Here are 1-3 brief analogies to describe RadNet:

• Quest Diagnostics or LabCorp for medical imaging scans (MRI, CT, mammography).

• The Tesla of diagnostic imaging, owning clinics and developing AI to interpret scans.

• Magnetic Resonance Imaging (MRI): A non-invasive medical imaging service that uses strong magnetic fields and radio waves to create detailed images of organs and tissues within the body.
• Computed Tomography (CT): A diagnostic imaging service utilizing X-rays and computer processing to produce cross-sectional images of the body, aiding in the diagnosis of various conditions.
• Positron Emission Tomography (PET) and Nuclear Medicine: Specialized imaging services that use radioactive tracers to visualize and measure metabolic activity, blood flow, and other physiological functions in the body.
• Mammography: A specific X-ray imaging service of the breast used to detect and diagnose breast diseases, including cancer.
• Ultrasound: A medical imaging service that uses high-frequency sound waves to create real-time images of internal body structures without using radiation.
• Diagnostic Radiology and Fluoroscopy: Services employing various forms of X-ray technology to visualize internal body structures and processes, helping to diagnose and guide treatment for medical conditions.
• Picture Archiving Communications Systems (PACS): Computerized systems developed and sold to store, retrieve, manage, distribute, and present medical images and data for diagnostic imaging centers.
• AI Suites and Solutions for Medical Imaging: Artificial intelligence software developed and deployed to enhance radiologist interpretation of medical images, with applications in mammography, lung, and prostate cancer detection.

RadNet, Inc. (RDNT) primarily provides outpatient diagnostic imaging services directly to individuals. While insurance companies cover a significant portion of the costs, the direct customers receiving the services are patients. Based on its business model of operating and managing imaging centers, RadNet serves the following major categories of customers:

1. Patients with Physician Referrals: These are individuals who require diagnostic imaging services, such as MRI, CT, or X-rays, as recommended or prescribed by their referring physicians (primary care doctors, specialists, etc.) for the diagnosis, monitoring, or treatment of medical conditions.
2. Patients for Preventative Screenings: This category includes individuals who utilize RadNet's services for routine or preventative screenings, such as mammography, often as part of general health maintenance or early disease detection.
3. Patients involved in Workers' Compensation or Personal Injury Cases: These are individuals whose diagnostic imaging needs arise from work-related injuries or accidents, with the services typically billed to workers' compensation carriers or other third-party liability insurers.

• Siemens Healthineers AG (XTRA: SHL, OTC: SMMNY)
• GE HealthCare Technologies Inc. (NASDAQ: GEHC)
• Koninklijke Philips N.V. (Euronext Amsterdam: PHIA, NYSE: PHG)

Howard G. Berger, M.D. President and Chief Executive Officer

Dr. Berger co-founded RadNet in 1980 and has served as its President and Chief Executive Officer since 1987. He also previously served as the Chief Financial Officer of RadNet, Inc. since 1987. He possesses over 25 years of experience in the development and management of successful healthcare businesses. Dr. Berger is Board Certified in Nuclear Medicine and received his Medical Degree from the University of Illinois Medical School.

Mark D. Stolper Executive Vice President and Chief Financial Officer

Mr. Stolper has held the position of Executive Vice President and Chief Financial Officer of RadNet since 2004. Before this role, he was an independent member of the company's Board of Directors. He is responsible for all financial functions and disciplines within the company.

Stephen M. Forthuber President and Chief Executive Officer, Eastern Operations

Effective January 7, 2026, Mr. Forthuber was promoted to President and Chief Executive Officer, Eastern Operations. Prior to this, he served as President and Chief Operating Officer for Eastern Operations since May 2017 and Chief Operating Officer of Eastern Operations since November 2006. He has 23 years of experience in the healthcare field, with 18 of those years dedicated exclusively to radiology practice management. Mr. Forthuber previously served in multiple roles at MMS, a private company providing outsourced Reimbursement Operations and Practice Management, eventually becoming its President and Chief Operating Officer for Eastern Operations.

Norman R. Hames President and Chief Executive Officer, Western Operations

Effective January 7, 2026, Mr. Hames was promoted to President and Chief Executive Officer, Western Operations. He previously served as President and Chief Operating Officer for Western Operations. With 20 years of industry experience, Mr. Hames oversees all aspects of facility operations for RadNet's Western Operations. Before joining RadNet, he was President and CEO of his own company, Diagnostic Imaging Services, Inc. (DIS), which owned and operated 14 multi-modality imaging centers across Southern California. His initial experience in operating imaging centers was gained at American Medical International (AMI).

Mital Patel Executive Vice President and Chief Operating Officer

Effective January 7, 2026, Ms. Patel was promoted to Executive Vice President and Chief Operating Officer. Prior to this promotion, she held the role of Executive Vice President of Financial Planning and Analysis and Chief Administrative Officer.

Key Risks to RadNet (RDNT)

1. Healthcare Reimbursement and Regulatory Pressures: RadNet, as a major provider of outpatient diagnostic imaging services, is highly susceptible to changes in healthcare reimbursement policies, particularly from government programs like Medicare and private insurers. Recent and ongoing reductions in the Medicare Physician Fee Schedule (MPFS) conversion factor have a direct impact on payment rates for many diagnostic imaging procedures, creating persistent revenue risk. The diagnostic imaging industry has faced significant reimbursement rate cuts for over a decade, with some high-volume procedures experiencing substantial reductions. Furthermore, the company is subject to regulatory scrutiny and the complex compliance requirements of the healthcare sector.
2. Technological Disruption, AI-Related Risks, and Competition: RadNet both provides diagnostic imaging services and develops and deploys AI suites and computerized systems (PACS). This dual involvement exposes the company to rapid technological advancements and intense competition. While AI offers benefits, it also carries inherent risks, including the potential for diagnostic mistakes due to algorithm errors, biases in training data, lack of transparency in AI decision-making, and ethical and liability concerns. Failure to keep pace with evolving imaging technologies or AI development, or intense competition from other technology providers and imaging centers adopting superior solutions, could impact RadNet's market position and require significant ongoing investment.
3. Increasing Operating Costs and Labor Shortages: The company faces significant challenges from rising operating costs, primarily driven by inflation in labor, equipment, and supplies. Wage increases for highly skilled radiology staff and other professional service providers can outpace revenue growth, directly pressuring the company's profit margins. The diagnostic imaging industry also contends with widespread staffing shortages and radiologist burnout, which can lead to operational inefficiencies, delayed patient care, and increased costs for recruitment and retention.

RadNet (RDNT) operates in several key addressable markets within the United States, including outpatient diagnostic imaging services, computerized systems for diagnostic imaging (PACS), and AI suites for radiologist interpretation in mammography, lung, and prostate cancer.

The addressable markets for RadNet's main products and services in the U.S. are as follows:

Outpatient Diagnostic Imaging Services

• The U.S. imaging services market was estimated at approximately USD 104.25 billion in 2025 and is projected to reach about USD 121.32 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 1.9% from 2026 to 2033. Other estimates place the U.S. imaging services market at USD 150.14 billion in 2025, with projections to reach around USD 276.31 billion by 2034 at a CAGR of 7.04% from 2025 to 2034.
• Specifically, the market size for Diagnostic Imaging Centers in the U.S., where RadNet operates a significant number of its centers, was approximately USD 26.3 billion in 2025 and is estimated to be USD 27.2 billion in 2026. RadNet itself is a major player, operating around 398 diagnostic imaging centers across the U.S.

Computerized Systems for the Diagnostic Imaging Industry (Picture Archiving Communications Systems - PACS)

• The U.S. Picture Archiving & Communication System (PACS) market was valued at approximately USD 981.08 million in 2023 and is expected to reach USD 1.27 billion by 2029, growing at a CAGR of 4.50%. Another report estimated the U.S. PACS System market size at USD 1080.99 million in 2024.

AI Suites to Enhance Radiologist Interpretation of Images (Mammography, Lung, and Prostate Cancer)

• The broader U.S. AI in oncology market was estimated at approximately USD 890.5 million in 2023 and is projected to reach USD 10,745.55 million by 2033, with a CAGR of 28.26% from 2024 to 2033.
• AI in Mammography (Breast Imaging): The U.S. Artificial Intelligence in Breast Imaging Market was valued at approximately USD 492.14 million in 2024. The global AI in cancer diagnostics market attributed approximately USD 0.50 billion to breast cancer in 2024, representing about 31% of that market.
• AI in Lung Cancer Diagnosis: Within the global AI in cancer diagnostics market, lung cancer accounted for approximately USD 0.42 billion in 2024, representing about 26% of the market.
• AI in Prostate Cancer Diagnosis: Prostate cancer's share in the global AI in cancer diagnostics market was valued at approximately USD 0.27 billion in 2024, making up roughly 17% of the market.

• Expansion of Imaging Center Network: RadNet is actively growing its footprint through both the development of new, "de novo" imaging centers and strategic acquisitions of existing facilities. In 2024, the company built nine new centers and had 13 projects in the pipeline for 2025. RadNet expanded into the Texas market in 2024 and entered the Midwest with the acquisition of six outpatient imaging centers from Northwest Radiology in Indianapolis in early 2026, which is expected to add $18 million in annual revenue. Additionally, the acquisition of Radiology Regional in Southwest Florida in January 2026 is projected to add approximately $100 million in revenue in 2026. This aggressive expansion strategy aims to increase capacity and meet rising demand in both existing and new markets.
• Growth in Advanced Imaging Modalities: The company anticipates continued strong performance and volume growth in higher-acuity, advanced imaging procedures such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography/Computed Tomography (PET/CT). These modalities have consistently shown double-digit volume increases, contributing significantly to revenue and a favorable shift in the overall business mix. For example, MRI volumes increased 11.7%, CT volumes increased 9.1%, and PET/CT volumes increased 17.5% in the first quarter of 2024 compared to the prior year.
• Development and Commercialization of Digital Health and AI Solutions: RadNet's Digital Health segment, particularly through its DeepHealth platform and the strategic acquisition of AI company Gleamer, is a significant driver of future revenue. The Gleamer acquisition, completed in early 2026, is expected to contribute approximately $30 million in Annual Recurring Revenue (ARR) in 2026. The total ARR for the Digital Health division is projected to approach $140 million by the end of 2026. These AI solutions are designed to enhance radiologist interpretation, automate workflows (especially in high-volume modalities like X-ray), and improve efficiency, addressing rising imaging volumes and radiologist shortages. RadNet also plans to expand sales and licensing of these AI solutions to external customers, reducing reliance on internal use.
• Strategic Joint Venture Partnerships: RadNet is actively pursuing and expanding its joint venture partnerships with health systems. These collaborations are expected to further boost growth by integrating RadNet's operational expertise and imaging technologies within broader healthcare networks, thereby increasing patient access and referral volumes.

Share Repurchases

• RadNet reported $0 in share buybacks as of December 31, 2024.
• A lack of free cash flow has limited the company's ability to execute share buybacks.

Share Issuance

• In June 2023, RadNet closed an underwritten public offering of 8,711,250 shares of its common stock at $29.75 per share, generating approximately $259.2 million in gross proceeds.
• The weighted average number of diluted shares outstanding was 75.2 million in 2025, 74.8 million in 2024, and 59.2 million in 2023.
• As of February 27, 2026, the number of common shares outstanding was 77,612,125.

Outbound Investments

• In 2025, RadNet acquired approximately eight imaging center segment companies for a total of $73.1 million through September, and acquired AI firms for its DeepHealth business including See-Mode Technologies ($29 million), iCAD ($103 million), Kheiron Medical Technologies ($1 million), and Alpha RT ($5 million).
• In 2026, RadNet acquired Paris-based Gleamer for up to €230 million (approximately $250 million), which is expected to add around $30 million in annual recurring revenue.
• Also in 2026, RadNet established its first presence in the Midwest by acquiring Northwest Radiology Network, P.C. in the Indianapolis area, which is expected to add approximately $18 million in annual revenue.

Capital Expenditures

• Capital expenditures were $98.8 million in 2021, including a $26.0 million opportunistic equipment purchase, and $105.7 million in 2022.
• For full-year 2025, capital expenditures amounted to $170.5 million for the Imaging Center segment.
• RadNet's guidance for capital expenditures in 2026 is projected to be between $140 million and $150 million. These investments primarily focus on strengthening core imaging operations and developing proprietary technologies like patient scheduling, image storage, and AI applications to improve quality and efficiency.